一种独特的抑制剂构造选择性地准了Gram阳性优先病原体的DNA聚合酶PolC
Mia Urem1,2, Annemieke H Friggen1, Nina Musch1
1Leiden University Center of Infectious Diseases (LUCID), Leiden University Medical Center, Leiden, The Netherlands.
Nature communications
|November 6, 2025
概括
针对PolC酶的新型抗微生物抑制剂提供了针对耐药性格拉姆阳性病原体的新策略. 结构洞察力揭示了这些抑制剂如何与DNA结合,阻止复制并为新的抗生素开发铺平道路.
科学领域:
- 微生物学 微生物学
- 结构生物学 结构生物学
- 药物发现 药物发现 药物发现
背景情况:
- 抗菌素耐药性 (AMR) 构成了全球健康的重大威胁,特别是来自格拉姆阳性病原体.
- 细菌复制聚合酶PolC的抑制剂代表了一种有前途的新类抗微生物药物.
- 目前尚不清楚PolC抑制剂活性背后的结构机制.
研究的目的:
- 阐明PolC抑制剂对格兰阳性病原体活性的结构基础.
- 为了描述ibezapolstat和ACX-801与Enterococcus faecium PolC.的结合情况.
- 为合理设计新型PolC向抗菌剂提供基础.
主要方法:
- 使用冷电子显微镜 (cryo-EM) 来确定Enterococcus faecium PolC.的结构.
- 解决了与DNA结合的PolC的结构,并与ibezapolstat和ACX-801.1复合在一起.
- 生物化学,生物信息学和遗传分析与结构数据相结合.
主要成果:
- 这些结构显示,ibezapolstat和ACX-801通过基配对相互作用与PolC活性部位内的DNA结合.
- 抑制剂与输入的脱氧三酸 (dGTP) 竞争,以融入DNA链.
- 在PolC中确定了一种保守的敏感性决定因素,受抑制剂的非平面形状的影响,从而形成了一个独特的结合口袋.
结论:
- 结构和生化数据提供了详细的了解PolC抑制剂如何在分子水平上起作用.
- 这项工作验证了PolC作为一种可行的药物标,用于对抗Clostridioides difficile,MRSA和VRE等格拉姆阳性病原体引起的感染.
- 这些发现支持继续开发PolC抑制剂,作为新一代针对优先病原体的抗微生物药物.
相关概念视频
Single-Strand DNA Binding Proteins
16.5K
For successful DNA replication, the unwinding of double-stranded DNA must be accompanied by stabilization and protection of the separated single strands of the DNA. This crucial task is performed by single-strand DNA-binding (SSB) proteins. They bind to the DNA in a sequence-independent manner, which means that the nitrogenous bases of the DNA need not be present in a specific order for binding of SSB proteins to it. The binding of SSB proteins straightens single-stranded DNA (ssDNA) and makes...
16.5K
Antibiotic Selection
59.3K
Overview
59.3K
Eukaryotic Transcription Inhibitors
10.9K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
Translesion DNA Polymerases
11.0K
Translesion (TLS) polymerases rescue stalled DNA polymerases at sites of damaged bases by replacing the replicative polymerase and installing a nucleotide across the damaged site. Doing so, TLS allows additional time for the cell to repair the damage before resuming regular DNA replication.
TLS polymerases are found in all three domains of life - archaea, bacteria, and eukaryotes. Of the different classes of TLS polymerases, members of the Y family are fitted with specialized structures that...
TLS polymerases are found in all three domains of life - archaea, bacteria, and eukaryotes. Of the different classes of TLS polymerases, members of the Y family are fitted with specialized structures that...
11.0K
Types of RNA
72.5K
Overview
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
72.5K
Targets for Drug Action: Overview
10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K


